Chemical Biology and Drug Design

MAY 17, 2024

Among a wide range of tyrosinase-regulating compounds, natural and synthetic derivatives of furochromenones, such as 8-methoxypsoralen (8-MOP), are known to both activate and inhibit tyrosinase. In the present study, we investigated these compounds for their potential as antagonists or agonists of tyrosinase.

Biochemical Assays 100

Biochemical Assays Regulations Production Research 100

Agency IQ

APRIL 12, 2024

BY RACHEL COE, MSC | APR 11, 2024 1:06 PM CDT Regulatory background: Product potency and assays As defined in statute , the FDA uses the term “potency” to refer to the “specific ability or capability” of a product to “effect a given result.”

Production 40

Production FDA Therapies Biochemical Assays 40

Agency IQ

JUNE 26, 2023

Because CDx are diagnostic devices, they are not considered part of a combination product but are regulated separately as medical devices. Further, footnote 7 in the document explains: “Examples of such clinical laboratory tests are commonly used and well understood biochemical assays (e.g.,

FDA 40

FDA Laboratories Clinical Trials Science 40

Drug Target Review

JANUARY 5, 2024

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. NIH R01 DA048153 (to D.P.S.), T he Journal of biological chemistry.

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59